EUVIMEDEUVIMED entdecken
Crossref

In silico designing of palbociclib loaded PLGA long-acting intramuscular injection for palliative therapy of HR+/HER2− metastatic breast cancer

Rutuja Suryawanshi iD, Anumol Joseph iD, Rajkumar Malayandi iD

Journal of Pharmacy and Pharmacology · 05.03.2026 · 78 (3)

DOI: 10.1093/jpp/rgag028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 23.03.2026. Verfasst von Rutuja Suryawanshi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hajipur, Export Promotion Industrial Park (EPIP), Zandaha R…. Hauptthemen laut MEDLINE: Breast Neoplasms, Piperazines, Pyridines, Polylactic Acid-Polyglycolic Acid Copolymer. Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Palbociclib (PBB) is an oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for the treatment of HR+/HER2− breast cancer. However, poor adherence and limited tolerability of oral administration often compromise its therapeutic effectiveness, especially in palliative care for metastatic conditions. Dose reductions are frequently required to manage toxicity, but lower doses can still provide effective tumour control with reduced neutropenia risk, thereby improving quality of life and progression-free survival. Developing a long-acting injectable (LAI) formulation of PBB offers significant advantages for sustained therapy in advanced-stage cancer management.

Methods

This study focuses on dose selection, release profile optimisation, and the design of sterile PBB-loaded PLGA microsphere suspensions for intramuscular (IM) administration using physiologically based pharmacokinetic (PBPK) modelling and simulations. The PBPK model, developed and validated with data from oral and intravenous routes, enabled the prediction of IM pharmacokinetics. Clinical target product profiles were defined based on IC50 and minimum steady-state concentration (Css, min). Key findings The dose optimisation study revealed that the rational selection of dose for both strengths, with an optimised sustained-release profile (Target 2, showing minimal initial burst and controlled release reaching ~55% by day 10.5 and ~90% by day 21), achieved the desired clinical quality target product profiles.

Conclusions

The developed model will further support polymer selection, specification setting, and drug-to-polymer ratio. Incorporating PBB’s physicochemical properties and host response helps guide rational formulation design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPiperazinesPyridinesPolylactic Acid-Polyglycolic Acid CopolymerAntineoplastic AgentsProtein Kinase InhibitorsHumansFemaleInjections, IntramuscularDelayed-Action PreparationsErb-b2 Receptor Tyrosine KinasesComputer SimulationPalliative CareModels, BiologicalMicrospheresDrug DesignDrug CarriersNeoplasm Metastasis

Stichwörter der Autor:innen

HR+/HER2− breast cancerPBPKlong-acting injectionsneutropeniapalbociclibpalliative care

Substanzen

palbociclibPiperazinesPyridinesPolylactic Acid-Polyglycolic Acid CopolymerDelayed-Action PreparationsErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsProtein Kinase InhibitorsERBB2 protein, humanDrug Carriers

Autor:innen und Institutionen

  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hajipur, Export Promotion Industrial Park (EPIP), Zandaha Road, NH322, Hajipur, Bihar 844102, India.

ORCID-Profile: Rutuja Suryawanshi, Anumol Joseph, Rajkumar Malayandi

Zitieren

APA

Suryawanshi, R., Joseph, A., & Malayandi, R. (2026). In silico designing of palbociclib loaded PLGA long-acting intramuscular injection for palliative therapy of HR+/HER2− metastatic breast cancer. Journal of Pharmacy and Pharmacology, 78(3). https://doi.org/10.1093/jpp/rgag028

Vancouver

Suryawanshi R, Joseph A, Malayandi R. In silico designing of palbociclib loaded PLGA long-acting intramuscular injection for palliative therapy of HR+/HER2− metastatic breast cancer. Journal of Pharmacy and Pharmacology. 2026;78(3). doi:10.1093/jpp/rgag028

BibTeX
@article{Suryawanshi2026,
  author = {Suryawanshi, Rutuja and Joseph, Anumol and Malayandi, Rajkumar},
  title = {In silico designing of palbociclib loaded PLGA long-acting intramuscular injection for palliative therapy of HR+/HER2− metastatic breast cancer},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  volume = {78},
  number = {3},
  doi = {10.1093/jpp/rgag028}
}
Kostenlos starten →